Abstract

We have previously shown that in vitro sensitivity to dexamethasone (DEX) stimulation in human endothelial cells is positively regulated by the glucocorticoid receptor (NR3C1, GR). The present study determined the role of differential GR transcriptional regulation in glucocorticoid sensitivity. We studied 25 human umbilical vein endothelial cells (HUVECs) that had been previously characterized as DEX-sensitive (n = 15), or resistant (n = 10). Real-time PCR analysis of GR 5′UTR mRNA isoforms showed that all HUVECs expressed isoforms 1B, 1C, 1D, 1F, and 1H, and isoforms 1B and 1C were predominantly expressed. DEX-resistant cells expressed higher basal levels of the 5′UTR mRNA isoforms 1C and 1D, but lower levels of the 5′UTR mRNA isoform 1F than DEX-sensitive cells. DEX treatment significantly decreased GRα and GR-1C mRNA isoform expression in DEX-resistant cells only. Reporter luciferase assays indicated that differential GR mRNA isoform expression was not due to differential promoter usage between DEX-sensitive and DEX-resistant cells. Analysis of promoter methylation, however, showed that DEX-sensitive cells have higher methylation levels of promoter 1D and lower methylation levels of promoter 1F than DEX-resistant cells. Treatment with 5-aza-2-deoxycytidine abolished the differential 5′UTR mRNA isoform expression between DEX-sensitive and DEX-resistant cells. Finally, both GRα overexpression and 5-aza-2-deoxycytidine treatment eliminated the differences between sensitivity groups to DEX-mediated downregulation of endothelial nitric oxide synthase (NOS3), and upregulation of plasminogen activator inhibitor 1 (SERPINE1). In sum, human endothelial GR 5′UTR mRNA expression is regulated by promoter methylation with DEX-sensitive and DEX-resistant cells having different GR promoter methylation patterns.

Highlights

  • Glucocorticoids are therapeutic agents used for reducing inflammation via targeting the glucocorticoid receptor (NR3C1, GR) of immune cells (Auphan et al 1995, Barnes 1998)

  • Differential GR mRNA isoform expression in human umbilical vein endothelial cells (HUVECs) according to DEX-sensitivity

  • Analysis of study group characteristics indicated that the pre-pregnancy maternal BMI and average systolic blood pressure were significantly higher in DEX-sensitive HUVECs compared to those of DEX-resistant cells (Supplementary Table 1), but the remaining parameters were not significantly different

Read more

Summary

Introduction

Glucocorticoids are therapeutic agents used for reducing inflammation via targeting the glucocorticoid receptor (NR3C1, GR) of immune cells (Auphan et al 1995, Barnes 1998). Glucocorticoids target the GR present in various other tissues, causing unwanted side effects. Glucocorticoids induce short-term side effects that include hypertension, dyslipidemia and thrombosis. Chronic synthetic glucocorticoidtherapy has been associated with endothelial dysfunction and increased risk of cardiovascular events such as myocardial infarction Kadmiel & Cidlowski 2013). These adverse events are mediated in part by glucocorticoid-dependent downregulation of endothelial nitric oxide synthase (NOS3) and upregulation of plasminogen activator inhibitor 1 (SERPINE1) (Wallerath et al 2004, Tamura et al 2015). Human studies have revealed significant human variability in response to both endogenous (cortisol) and synthetic glucocorticoids (Ito et al 2006, Kino 2007), but the mechanisms remain undetermined

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call